5-methoxy-dimethyltryptamine liquid intranasal (BPL-002) / Beckley Psytech - LARVOL DELTA

Analysis of drugs of abuse and contaminants in individuals under drug surveillance programs: A study in hair samples. (PubMed, Forensic Sci Int) - "Liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods were developed for the detection of some drugs (25B-NBOMe, 25C-NBOMe, 25E-NBOH, 2C-C, 2C-I, 3,4-MDPHP, 3-MeO-PCP, 5F-MDMB-PINACA, 5-MeO-DMT, cannabidiol, ethylone, JWH 073, ketamine, mephedrone and UR-144) and drug adulterants (levamisole, phenacetin, strychnine); other substances including cocaine, amphetamines, benzodiazepines, opioids, cannabinoids were also analysed. CBN also showed notable associations with cocaine (16 cases) and benzoylecgonine (22 cases). These findings provide important insights into the evolving drug landscape in Brazil and highlight the effectiveness of hair analysis as a tool for monitoring drug use."

Journal

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects (clinicaltrials.gov) - P1 | N=51 | Recruiting | Sponsor: Beckley Psytech Limited | Trial completion date: Mar 2022 ➔ Jul 2022 | Trial primary completion date: Mar 2022 ➔ Jul 2022

Trial completion date • Trial primary completion date

A narrative synthesis of research with 5-MeO-DMT. (PubMed, J Psychopharmacol) - "5-MeO-DMT is a potentially useful addition to the psychedelic pharmacopoeia because of its short duration of action, relative lack of visual effects and putatively higher rates of ego-dissolution and mystical experiences. We conclude that further clinical exploration is warranted, using similar precautions as with other classic psychedelics."

Journal

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Beckley Psytech Limited

Clinical • New P1 trial

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs (Businesswire) - "Beckley Psytech...announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC) investors to fund its promising research programmes. The Series B financing was initially set at $50m and was upsized to $80m...Beckley Psytech will use the proceeds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression."

Financing • CNS Disorders • Depression